Compare AISP & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | CRDF |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.9M | 86.8M |
| IPO Year | N/A | 2012 |
| Metric | AISP | CRDF |
|---|---|---|
| Price | $2.23 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 658.9K | ★ 1.3M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $222.88 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.03 | $1.16 |
| 52 Week High | $7.20 | $4.56 |
| Indicator | AISP | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 37.14 | 46.17 |
| Support Level | $2.11 | $1.18 |
| Resistance Level | $2.39 | $1.66 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 16.59 | 52.17 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.